Merck outlines oncology data and research investment for Merck & Co. stock

Published on 10/17/2026 at 10:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck announced new oncology presentations on October 13. The update details what it means for Merck & Co. stock.

Research investment and oncology calendar

Merck announced new oncology presentations on October 13, 2026.
Merck inaugurated its ADVANCE facility on October 14, 2026.
The company plans an oncology investor event for October 26, 2026.

Extreme close-up macro photograph of a single white pharmaceutical tablet filling the entire frame. A precise central score line bisects the tablet horizontally, with a shallow embossed press mark from tablet manufacturing tooling. Fine powder granule tex — Merck US58933Y1055 Tabletten-Makro: Weiße Tablette mit Bruchrille und Tablettenpresse-Spur im extremen Nahaufnahme-Zoom, Illustration mit AI erstellt.

Merck outlined new oncology data for presentation at the European Society for Medical Oncology Congress and inaugurated a research facility during the week ending October 17, 2026. The company’s announcements were dated October 13 and October 14, respectively.

Market context: Market report S&P 500.

Weekend trading

Xetra and the primary exchanges are closed on October 17, 2026. The next price is shown from the start of trading by the continuously updated real-time quote of Merck & Co. stock.

Research investment

On October 14, Merck inaugurated its ADVANCE bioanalytical research facility at the company’s West Point, Pennsylvania, campus. Merck said its investment in ADVANCE and the nearby Spring House Innovation Park totals approximately $550 million. The facility is designed to use automated robotic systems and digital artificial-intelligence capabilities to support analysis of biological samples from clinical development programs. These details were reported in Merck’s company release.

Oncology calendar

On October 13, Merck said first-time results from three pivotal clinical trials would be presented at late-breaking Presidential Symposia during the ESMO Congress in Madrid from October 23 through October 27. The company also scheduled an oncology investor event for October 26 at 7:30 p.m. CET. The announcement is documented in Merck’s ESMO release.

Coming dates

The ESMO Congress is scheduled for October 23 through October 27, followed by Merck’s oncology investor event on October 26. The company has also scheduled its third-quarter 2026 sales and earnings conference call for October 29, according to the company announcement identified in its investor materials.